Stay updated on REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 on the page. No other study content or functionality changes are evident.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a dedicated Locations section with Florida listed as a location, and removed the Florida Locations reference. The revision note was updated from v3.3.2 to v3.3.3, and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.2%

- Check53 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedThe funding-status warning about government delays has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedResults for NCT03515629 have been posted, including updates to primary and secondary outcomes and the overall study status. The primary endpoint PFS is noted as not assessed due to insufficient data, with other outcomes outlined.SummaryDifference0.4%

- Check103 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference4%

Stay in the know with updates to REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page.